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Circulating Fibroblast Growth 
Factor-23 Levels are Associated 
with an Increased Risk of Anemia 
Development in Patients with 
Nondialysis Chronic Kidney Disease
Ki Heon Nam1, Hyoungnae Kim1, Seong Yeong An1, Misol Lee1, Min-Uk Cha1, Jung Tak Park1, 
Tae-Hyun Yoo1, Kyu-Beck Lee2, Yeong-Hoon Kim3, Su-Ah Sung4, Joongyub Lee5, Shin-Wook 
Kang1,7, Kyu Hun Choi1, Curie Ahn  6 & Seung Hyeok Han  1
Fibroblast growth factor-23 (FGF23) is an established biomarker of adverse outcomes in patients with 
chronic kidney disease (CKD). Several cross-sectional studies have suggested a possible association 
between FGF23 and anemia in these patients. In this large-scale prospective cohort study, we investigated 
this relationship and examined whether high FGF23 levels increase the risk of incident anemia. This 
prospective longitudinal study included 2,089 patients from the KoreaN cohort study for Outcome in 
patients With CKD. Anemia was defined as hemoglobin level <13.0 g/dl (men) and <12.0 g/dl (women). 
Log-transformed FGF23 significantly correlated with hepcidin but inversely correlated with iron profiles 
and hemoglobin. Multivariate logistic regression showed that log-transformed FGF23 was independently 
associated with anemia (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.04–1.24, P = 0.01). Among 
1,164 patients without anemia at baseline, 295 (25.3%) developed anemia during a median follow-up of 
21 months. In fully adjusted multivariable Cox models, the risk of anemia development was significantly 
higher in the third (hazard ratio [HR], 1.66; 95% CI, 1.11–2.47; P = 0.01) and fourth (HR, 1.84; 95% 
CI, 1.23–2.76; P = 0.001) than in the first FGF23 quartile. In conclusion, high serum FGF23 levels were 
associated with an increased risk for anemia in patients with nondialysis CKD.
Anemia is one of the most common complications in chronic kidney disease (CKD), and its prevalence increases 
progressively as kidney function declines1. The recent National Health and Nutrition Examination Survey 
reported that anemia was twice as prevalent in persons with CKD (15.4%) as that in the general population (7.6%) 
in the United States2. In addition, anemia is closely associated with poor quality of life and adverse outcomes such 
as left ventricular hypertrophy, cardiovascular events, and increased mortality in patients with CKD3–5. Although 
the mechanism for anemia in CKD is primarily due to failure of erythropoietin (EPO) production in response 
to decreased hemoglobin concentration6, other potential factors such as chronic inflammation, iron deficiency, 
malnutrition, increased destruction of red blood cells, and vitamin D deficiency also contribute to the pathogen-
esis of renal anemia7–9.
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone that is crucial for maintaining normal phos-
phate and vitamin D homeostasis10,11. FGF23 levels increase gradually with diminishing renal function, and it 
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seems to be an adaptive mechanism to prevent hyperphosphatemia12. Recently, elevated FGF23 levels have been 
shown to be associated with adverse outcomes, such as progression of kidney disease13,14, vascular calcification15, 
left ventricular hypertrophy16, cardiovascular events17,18, and increased mortality14,17,19. Considering that FGF23 
and anemia are nontraditional risk factors for adverse outcomes in patients with CKD, and both are reciprocally 
changed according to kidney function, it would be intriguing to explore the relationship between FGF23 and ane-
mia in CKD. Interestingly, the inhibitory effect of FGF23 on erythropoiesis was demonstrated in an experimental 
study20. However, only few human studies have suggested a possible association between FGF23 and anemia in 
patients with CKD21–23. In most studies, the causality between FGF23 and anemia could not be explained because 
this relationship was analyzed through a cross-sectional approach. The purpose of this study was, therefore, to 
further clarify the relationship between FGF23 levels and anemia in patients with CKD and to examine whether 
high FGF23 levels increase the future development of anemia, in a large-scale prospective cohort study.
Materials and Methods
Study design and population. The KoreaN cohort study for Outcome in patients With Chronic Kidney 
Disease (KNOW-CKD) is a prospective nationwide cohort study investigating various clinical courses and risk 
factors for the progression of CKD in Korean patients. Patients aged between 20 and 75 years with CKD stage 
1–5 before dialysis who voluntarily provided informed consent were enrolled from nine university-affiliated ter-
tiary-care hospitals throughout Korea between June 2011 and February 2015. The detailed design and method of 
the study have previously been described elsewhere (NCT01630486 at http://www.clinicaltrials.gov)24. Among 
2,238 patients in the KNOW-CKD cohort, 149 patients with missing data for hemoglobin, hepcidin, iron profiles, 
and C-terminal FGF23 (FGF23) levels were excluded. Finally, 2,089 patients were included in the present analysis 
(Fig. 1).
Data collection. Baseline sociodemographic information and laboratory data were obtained from the 
KNOW-CKD database. The resting blood pressure (BP) in the clinic was measured with an electronic sphyg-
momanometer, and body mass index (BMI) was determined using the formula “weight (kg)/height (m2). Serum 
sample collected for initial study measurements sent to the central laboratory of the KNOW-CKD study (Lab 
Genomics, Seongnam, Republic of Korea) and were stored at −80 °C in deep freezer. Along with blood samples, 
urine samples were also immediately sent to central lab and subject for proteinuria measurement. Laboratory 
tests were obtained every 6 months in the first year and then annually thereafter. Serum creatinine was measured 
using an isotope dilution mass spectrometry-traceable method, and estimated glomerular filtration rate (eGFR) 
was calculated using the four-variable Modification of Diet in Renal Disease equation25. Serum levels of hepcidin 
were measured using commercially available ELISA kits (DRG Instruments GmBH, Marburg, Germany). Anemia 
was defined as hemoglobin levels of <13.0 g/dL for men and <12.0 g/dL for women according to World Health 
Organization (WHO) criteria. Transferrin saturation (TSAT) was calculated using the ratio of serum iron and 
total iron-binding capacity. Iron deficiency was defined as ferritin <100 ng/mL or TSAT <20%.
Serum C-terminal FGF23 concentration was measured using enzyme-linked immunosorbent assay (ELISA; 
Immutopics, San Clemente, CA, USA). Regarding sensitivity of FGF23 assay, the 95% confidence limit on 20 
duplicate determinations of the 0 RU/ml standard is 1.5 RU/ml. Precision of FGF23 assay was carried out for 
quality control measures. Intra-assay precision was calculated from 20 duplicate determinations of two samples 
each performed in a single assay. Coefficient of variations for FGF level of 33.7 and 302 RU/ml were 2.4% and 
1.4%, respectively. In addition, inter-assay precision was calculated from duplicate determinations of two sam-
ples performed in 10 assays. Coefficient of variations for FGF level of 33.6 and 293 RU/mL were 4.7% and 2.4%, 
respectively.
Figure 1. Flow chart for patients enrollment and analyses.
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Study endpoint. We first performed a cross-sectional analysis to clarify the relationship between serum 
FGF23 levels and anemia in 2,089 patients using the baseline data. Then, we further examined whether elevated 
FGF23 levels increase the future development of anemia in 1,164 patients who had no anemia at baseline (Fig. 1). 
For this analysis, the primary outcome was newly developed anemia during the follow-up period.
Statistical analyses. All analyses were performed with IBM SPSS Statistics version 21 (IBM Corp., 
Armonk, NY, USA) and SAS version 9.4 (SAS Institute, Cary, NC, USA). All variables with a normal distri-
bution were expressed as mean ± standard deviation. If data did not have a normal distribution, they were 
expressed as median and interquartile range (IQR). Categorical variables were expressed as number and 
proportion. Comparisons were made using one-way analysis of variance for continuous variables and the 
chi-square test for categorical variables, as required. Pearson’s correlation test was used to evaluate the relation-
ship between covariables, and a multivariable linear regression analysis for hemoglobin level was performed 
after adjustment for age, sex, presence of diabetes mellitus (DM), BMI, systolic BP (SBP), Charlson comor-
bidity index (CCI), smoking status, eGFR, albumin, phosphorus, 1,25(OH)2 vitamin D, presence of iron defi-
ciency, hepcidin, C-reactive protein (CRP), proteinuria, and anemia treatment including iron replacement and 
EPO-stimulating agent (ESA). In addition, a multivariable-adjusted logistic regression analysis was conducted 
to determine whether FGF23 was associated with anemia as defined based on WHO criteria. The results were 
presented as odds ratios (ORs) and 95% confidence intervals (CIs). Among 1,164 patients without baseline 
anemia, the cumulative anemia-free survival rates were estimated using the Kaplan–Meier method and differ-
ences between survival curves were compared with the log-rank test. Furthermore, multivariate Cox regression 
models for the development of anemia were constructed after rigorous and stepwise adjustments for confound-
ing factors. Model 1 was the unadjusted model with no covariables. Model 2 included adjustment for age, sex, 
DM, BMI, SBP, CCI, and smoking. We constructed model 3 by adding eGFR, albumin, phosphorus, 1,25(OH)2 
vitamin D, presence of iron deficiency, hepcidin, CRP, and proteinuria to model 2. Moreover, model 4 included 
iron replacement and ESA therapy in addition to model 3 variables. The results were presented as hazard ratios 
(HRs) and 95% CIs. We also examined the association between FGF23 levels and the development of anemia 
through subgroup analysis using a fully adjusted multivariate Cox regression model. The patients were strat-
ified according to sex, history of DM, presence of iron deficiency, treatment with renin-angiotensin system 
(RAS) blockers, and median values of age, SBP, BMI, CCI, eGFR, albumin, CRP, and 1,25(OH)2 vitamin D. 
P < 0.05 was considered statistically significant for all analyses.
Ethics statement. We carried out the study in accordance with the Declaration of Helsinki, and the study 
was approved by the institutional review board of each participating clinical center, as follows: Seoul National 
University Hospital (1104–089–359), Seoul National University Bundang Hospital (B-1106/129-008), Yonsei 
University Severance Hospital (4-2011-0163), Kangbuk Samsung Medical Center (2011-01-076), Seoul St. Mary’s 
Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji General Hospital (201105-01), Chonnam National 
University Hospital (CNUH-2011-092), and Pusan Paik Hospital (11-091) in 2011.
Results
Patient characteristics according to fibroblast growth factor-23. The median serum FGF23 level 
was 19.6 RU/ml. The median value of FGF23 in each quartiles, from the first to the fourth, was 0.0 (IQR, 0.0–0.4; 
range, 0.0–1.7), 9.5 (IQR, 4.8–15.9; range, 1.8–19.6), 25.5 (IQR, 22.3–29.8; range, 19.7–34.6), and 52.9 (IQR, 41.3–
75.3; range, 34.7–774.0). According to FGF23 quartiles, we categorized the study subjects into four groups and 
compared their baseline characteristics (Table 1). The mean age was 53.6 ± 12.2 years and 1,275 patients (61.0%) 
were male. The mean eGFR was 50.3 ± 30.2 mL·min−1·1.73 m−2 and was significantly lower in high FGF23 quar-
tiles than in low quartiles (P < 0.001). The prevalence of DM and serum levels of hepcidin, phosphorus, and intact 
parathyroid hormone were higher, whereas calcium and 1,25(OH)2 vitamin D levels were lower in high FGF23 
quartiles (P < 0.001 for all). The mean hemoglobin levels were 12.8 ± 2.0 g/dL and were significantly lower in high 
FGF23 quartiles (P < 0.001). Regarding iron profiles, serum iron levels and TSAT were also lower in high FGF23 
quartiles. However, serum ferritin levels did not differ among quartiles. There were more patients who received 
iron replacement and ESA therapy in the high FGF23 quartiles.
Relationship between fibroblast growth factor-23 levels and baseline anemia. In Pearson cor-
relation analyses, log-transformed FGF23 was inversely correlated with eGFR, albumin, calcium, 1,25(OH)2 
vitamin D, iron, TSAT, and hemoglobin (Fig. 2), whereas it was positively correlated with CCI, phosphorus, 
intact parathyroid hormone, hepcidin, and proteinuria. However, age, BMI, CRP, and ferritin were not corre-
lated with FGF23. We then performed in-depth analyses to clarify the association between FGF23 and anemia. 
In a multivariable linear regression analysis adjusted for confounding factors, there was a significant inverse 
relationship between log-transformed FGF23 and hemoglobin levels (β = −0.067, P = 0.004; Table 2). This 
finding was further strengthened in a multivariable logistic model (Table 3). After rigorous adjustment of con-
founders, log-transformed FGF23 was independently associated with anemia (OR, 1.14; 95% CI, 1.04–1.24, 
P = 0.01). When FGF23 quartiles were entered as a categorical variable in the model, the highest quartile of 
FGF23 was significantly associated with anemia compared with the lowest quartile (OR, 1.72; 95% CI, 1.19–
2.50, P = 0.004).
High fibroblast growth factor-23 levels increase the development of anemia. We further 
investigated whether FGF23 levels increase the future development of anemia. To this end, we selected 1,164 
patients without anemia at baseline measurement. During the median follow-up duration of 21 (IQR, 7–38) 
months, 295 (25.3%) patients developed anemia. Anemia occurred in 48 (16.5%), 63 (21.6%), 91 (31.3%), and 
93 (32.0%) patients in the first, second, third, and fourth quartile of FGF23, respectively (P < 0.001, Table 4). The 
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Kaplan–Meier curves for anemia-free survival according to FGF23 quartiles are presented in Fig. 3. The time 
to the development of anemia was significantly shorter in high FGF23 quartiles (P = 0.009 for first vs. second; 
P < 0.001 for first vs. third and fourth). An in-depth analysis on the association between FGF23 levels and the 
development of anemia was performed using multivariable Cox regression models (Table 5). The crude HRs for 
incident anemia were 1.65 (95% CI, 1.13–2.40; P = 0.009), 2.55 (95% CI, 1.80–3.62; P < 0.001), and 2.94 (95% CI, 
2.07–4.17; P < 0.001) in the second, third, and fourth quartile compared with the first quartile. Further stepwise 
Variables
FGF23 quartiles
Total p-value
Quartile 1 
(0.0–1.7)
Quartile 2 
(1.8–19.6)
Quartile 3 
(19.7–34.6)
Quartile 4 
(34.7–774.0)
Number 522 522 523 522 2,089
Age (years) 52.6 ± 12.4 53.0 ± 12.2 54.6 ± 11.9 54.0 ± 12.4 53.6 ± 12.2 0.04
Sex (Male, %) 321 (61.5) 318 (60.9) 345 (66.0) 291 (55.7) 1,275 (61.0) 0.01
Smoking (n, %) 238 (45.6) 232 (44.8) 262 (50.1) 240 (46.0) 972 (46.5) 0.41
DM (n, %) 140 (26.8) 145 (27.8) 189 (36.1) 236 (45.2) 710 (34.0) <0.001
HTN (n, %) 491 (94.1) 503 (96.4) 508 (97.1) 506 (96.9) 2,008 (96.9) 0.41
BMI (kg/m2) 24.5 ± 3.2 24.6 ± 3.4 24.7 ± 3.5 24.4 ± 3.5 24.5 ± 3.4 0.65
SBP (mmHg) 127.9 ± 15.7 126.6 ± 14.7 127.7 ± 16.5 132.0 ± 18.3 128.5 ± 16.5 <0.001
DBP (mmHg) 77.1 ± 11.3 76.2 ± 10.8 76.1 ± 10.9 78.0 ± 11.6 94.1 ± 11.7 0.02
MAP (mmHg) 94.0 ± 11.5 93.0 ± 11.0 93.3 ± 11.5 96.0 ± 12.6 76.9 ± 11.2 <0.001
Anemia (n, %) 165 (31.6) 178 (34.1) 253 (48.4) 329 (63.0) 925 (44.3) <0.001
Charlson comorbidity index 1.9 ± 1.6 2.1 ± 1.6 2.5 ± 1.5 2.8 ± 1.6 2.3 ± 1.6 <0.001
Creatinine (mg/dl) 1.5 ± 0.8 1.5 ± 0.8 1.9 ± 1.1 2.3 ± 1.5 1.8 ± 1.1 <0.001
eGFR (ml/min/1.73 m2) 59.1 ± 30.1 56.8 ± 31.2 45.6 ± 26.7 39.8 ± 28.5 50.3 ± 30.2 <0.001
CKD stage
  1 (n, %) 116 (22.2) 106 (20.3) 61 (11.7) 53 (10.2) 336 (16.1) <0.001
  2 (n, %) 137 (26.2) 105 (20.1) 86 (16.4) 64 (12.3) 392 (18.8) <0.001
  3 (n, %) 183 (35.1) 218 (41.8) 211 (40.3) 170 (32.6) 782 (37.4) 0.006
  4 (n, %) 72 (13.8) 82 (15.7) 133 (25.4) 162 (31.0) 439 (21.0) <0.001
  5 (n, %) 14 (2.7) 11 (2.1) 32 (6.1) 73 (14.0) 130 (6.2) <0.001
WBC (x103/mm3) 6.5 ± 2.0 6.6 ± 1.8 6.7 ± 1.9 6.6 ± 2.0 6.6 ± 1.9 0.26
Hemoglobin (g/dl) 13.3 ± 1.8 13.2 ± 1.9 12.8 ± 2.1 12.0 ± 2.0 12.8 ± 2.0 <0.001
Platelet (x103/mm3) 228.8 ± 62.2 231.0 ± 58.0 231.9 ± 59.8 232.2 ± 65.7 231.0 ± 61.5 0.81
Iron (µg/dl) 95.5 ± 35.0 98.1 ± 36.6 93.6 ± 34.6 83.2 ± 32.8 92.6 ± 35.2 <0.001
Ferritin (ng/ml)* 101.5(58.6–176.0)
91.0
(52.2–161.9)
100.3
(53.6–186.3)
101.0
(49.4–175.2)
98.3
(53.3–175.7) 0.45
Transferrin saturation (%) 32.2 ± 11.7 33.1 ± 12.7 31.8 ± 11.8 29.4 ± 11.9 31.7 ± 12.1 <0.001
Hepcidin (ng/ml)* 11.5(5.8–22.8)
11.7
(6.1–21.5)
14.4
(7.2–25.8)
16.5
(7.8–30.4)
13.4
(6.6–25.1) <0.001
Total cholesterol (mg/dl) 176.5 ± 38.3 175.4 ± 37.3 172.8 ± 39.7 173.1 ± 42.2 174.4 ± 39.4 0.37
Albumin (g/dl) 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.1 ± 0.5 4.2 ± 0.4 <0.001
Calcium (mg/dl) 9.2 ± 0.5 9.2 ± 0.5 9.1 ± 0.5 9.0 ± 0.6 9.1 ± 0.5 <0.001
Phosphate (mg/dl) 3.6 ± 0.6 3.6 ± 0.6 3.7 ± 0.6 4.0 ± 0.8 3.7 ± 0.7 <0.001
iPTH (pg/ml)* 44.5(29.0–68.9)
46.1
(31.2–70.3)
53.0
(35.0–86.3)
69.0
(41.6–121.8)
51.6
(33.2–84.7) <0.001
1,25(OH)2 vitamin D (pg/ml) 32.1 ± 17.2 29.2 ± 13.3 27.4 ± 12.7 25.7 ± 5.3 28.6 ± 14.4 <0.001
FGF23 (RU/ml)* 0.03(0.0–0.4)
9.5
(4.8–15.9)
25.5
(22.3–29.8)
52.9
(41.3–75.3)
19.6
(1.7–34.6) <0.001
CRP (mg/dl)* 0.7 (0.2–1.6) 0.6 (0.2–1.4) 0.6 (0.3–1.6) 0.7 (0.2–2.2) 0.6 (0.2–1.6) 0.04
Proteinuria (g/24 h)* 0.4 (0.1–1.1) 0.5 (0.2–1.2) 0.7 (0.2–1.9) 0.7 (0.3–2.2) 0.5 (0.2–1.6) <0.001
Treatment
  RAS blockers (n, %) 446 (85.4) 452 (86.6) 436 (83.4) 448 (85.8) 1,782 (85.3) 0.50
  Statin (n, %) 262 (50.2) 273 (52.3) 277 (53.0) 267 (51.1) 1,079 (51.8) 0.84
  Iron replacement (n, %) 50 (9.6) 62 (11.9) 82 (15.7) 113 (21.6) 179 (8.6) <0.001
  ESA therapy (n, %) 19 (3.6) 27 (5.2) 35 (6.7) 78 (14.9) 167 (7.5) <0.001
Table 1. Baseline characteristics of patients according to FGF23 quartile. All data are expressed as mean ± SD 
or *median (and interquartile range) Abbreviations: FGF23, fibroblast growth factor 23; DM, diabetes mellitus; 
HTN, hypertension; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, 
mean arterial pressure; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; WBC, white 
blood cell; iPTH, intact parathyroid hormone; S-Klotho, soluble α-Klotho; CRP, C-reactive protein; RAS, renin-
angiotensin system; ESA, erythropoiesis-stimulating agent.
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multivariable adjusted models yielded similar results. In the fully adjusted model, the risk of developing anemia 
was significantly higher in the third (HR, 1.66; 95% CI, 1.11–2.47; P = 0.01) and fourth (HR, 1.84; 95% CI, 1.23–
2.76; P = 0.003) quartile of FGF23 compared with the first quartile. When FGF23 was treated as a continuous 
variable, a significant association between FGF23 and anemia remained unaltered (HR for every 1 log increase, 
1.17; 95% CI, 1.07–1.29; P = 0.001).
Subgroup analyses. We also investigated the relationship between FGF23 and the development of anemia 
in several subgroups stratified by age, sex, presence of diabetes, SBP, BMI, CCI, eGFR, albumin, 1,25(OH)2 vita-
min D, CRP, and iron deficiency status. The results showed the consistent direction of the impact of FGF23 with 
Figure 2. Correlation between FGF23 and hemoglobin.
Variables
Hemoglobin (g/dl)
β
95% CI
P-valueLower Upper
Age (per 10 years) −0.032 −0.094 0.030 0.32
Sex (male) 1.296 1.098 1.494 <0.001
BMI (per 1 kg/m2) 0.079 0.058 0.100 <0.001
Diabetes mellitus −0.366 −0.585 −0.147 0.001
Smoking −0.065 −0.245 0.115 0.48
CCI (per 1score) −0.100 −0.179 −0.021 0.01
SBP (per 1 mmHg) −0.003 −0.007 0.002 0.21
eGFR (per 1 ml/min per 1.73 m2) 0.015 0.011 0.018 <0.001
Albumin (per 1 g/dl) 0.926 0.732 1.119 <0.001
Phosphorus (per 1 mg/dl) −0.453 −0.568 −0.338 <0.001
1,25(OH)2 vitamin D (per 1 pg/ml) 0.001 −0.004 0.006 0.66
Iron deficiency −0.325 −0.484 −0.166 <0.001
Hepcidin (per 1 log)* −0.150 −0.234 −0.067 <0.001
CRP (per 1 log)* −0.019 −0.122 0.085 0.72
FGF23 (per 1 log)* −0.067 −0.114 −0.021 0.004
Proteinuria (per 1 log)* 0.044 −0.006 0.094 0.09
Iron replacement −0.862 −1.079 −0.645 <0.001
ESA therapy −0.361 −0.653 −0.069 0.02
Table 2. Multivariable linear regression analysis of factors associated with hemoglobin levels (cross- sectional 
analysis). Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; SBP, systolic blood pressure; 
eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; ESA, 
erythropoiesis-stimulating agent. *log transformed.
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respect to anemia in most stratified groups (Fig. 4). Notably, this association was observed particularly in nondia-
betics, patients aged <50 years, patients treated with RAS blockers, patients with iron deficiency, or patients with 
SBP <130, BMI <25 kg/m2, CCI <3, eGFR >30 ml·min−1·1.73 m−2 or albumin ≥ 4.3 g/dl.
Discussion
In this prospective cohort study, we demonstrated the inverse relationship between serum FGF23 and hemo-
globin in patients with nondialysis CKD. In addition, we also showed that high serum FGF23 levels were sig-
nificantly associated with an increased risk for the development of anemia even after a rigorous adjustment for 
multiple confounding factors. This association was particularly evident in patients treated with RAS blockers, 
patients with young age, relatively preserved eGFR, low comorbid burden, and iron deficiency. Our findings are 
of great clinical importance, as anemia is a frequent complication in patients with CKD and is associated with 
Univariate analysis Multivariate analysis*
OR (95% CI) P-value OR (95% CI) P-value
FGF23 quartile
Quartile 1 (n = 522) Reference Reference
Quartile 2 (n = 522) 1.11 (0.86–1.44) 0.43 0.97 (0.67–1.40) 0.87
Quartile 3 (n = 523) 2.10 (1.63–2.70) <0.001 1.31 (0.91–1.88) 0.14
Quartile 4 (n = 522) 3.49 (2.70–4.50) <0.001 1.72 (1.19–2.50) 0.004
FGF23 (per 1 log) 1.36 (1.26–1.45) <0.001 1.14 (1.04–1.24) 0.01
Table 3. Multiple logistic regression analysis of factors associated with anemia (cross- sectional analysis). Note: 
FGF23 entered as a categorical and continuous form (log transformed). *Adjusted for age, sex, DM, BMI, SBP, 
CCI, smoking, eGFR, albumin, phosphorus, 1,25(OH)2 vitamin D, iron deficiency, log-transformed hepcidin, 
log-transformed CRP, log-transformed proteinuria, and iron/ESA therapy. Abbreviations: FGF23, fibroblast 
growth factor 23; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; CCI, Charlson 
comorbidity index; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; ESA, erythropoiesis-
stimulating agent.
All
Patients without baseline anemia (n = 1,164)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-for 
trendN (%) N (%) N (%) N (%)
Newly developed 
anemia during 
follow-up
295 (25.3%) 48 (16.5%) 63 (21.6%) 91 (31.3%) 93 (32.0%) <0.001
Table 4. Clinical outcomes according to baseline FGF23 quartile. Abbreviations: FGF23, fibroblast growth 
factor 23.
Figure 3. Cumulative curves of anemia development according to FGF23 quartiles for patients without anemia 
at baseline.
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adverse outcomes3–5. Although there are well-established risk factors for anemia, our study suggests that FGF23 
can also be a useful biomarker of incident anemia in patients with nondialysis CKD.
Studies that have evaluated the relationship between FGF23 and anemia have yielded conflicting results. To 
date, there have been only five studies that have specifically addressed this issue. In a study by Akalin et al., there 
was no association between FGF23 and hemoglobin levels in 89 patients undergoing hemodialysis26. In addition, 
a recent observational study by Honda et al. showed no significant relationship between FGF23 and hemoglobin 
levels in 282 patients undergoing hemodialysis27. These findings were contradicted by two other studies: one on 
patients undergoing peritoneal dialysis and one on patients with CKD before dialysis treatment21,22. These studies 
showed a significant inverse association between FGF23 and anemia. However, these studies are limited by their 
small sample size and cross-sectional analyses. Furthermore, as dialysis patients are more likely to receive iron 
preparation and ESA, interpretation should be made carefully in these patients. Of note, our study has a larger 
sample size than most previous studies, which thus assures power to detect statistical significance. In addition, we 
demonstrated that high FGF23 level increased the future development of anemia in a longitudinal observation of 
a CKD cohort. Our findings particularly corroborated findings from a recent publication by the Chronic Renal 
Insufficiency Cohort Study investigators23, indicating that elevated FGF23 is associated with prevalent anemia, 
change in hemoglobin over time, and the development of anemia.
The mechanism responsible for FGF23-associated anemia is unknown. Although anemia in CKD is a multi-
factorial disorder, it is well explained by insufficient EPO, a hormone that stimulates red blood cell production 
in the bone marrow in response to low oxygen levels in the blood6,8. EPO production is impaired at any given 
hematocrit concentration in patients with decreased renal function6. Interestingly, one experimental study found 
that loss of FGF23 resulted in markedly augmented erythropoiesis in peripheral blood and bone marrow of young 
adult mice, which can be accounted for by elevated serum EPO levels and EPO mRNA synthesis in the bone 
marrow, liver, and kidney20. Conversely, in this study, administration of FGF23 in wild-type mice resulted in a 
decrease in erythropoiesis20. These experimental evidence together with clinical research studies including ours 
suggest that FGF23 is a negative regulator of erythropoiesis. Unfortunately, a correlation between FGF23 and 
EPO could not be determined in our study because the EPO levels were not measured. Future studies are required 
to clarify the relationship between FGF23 and EPO.
Vitamin D deficiency has been suggested as a risk factor for anemia in patients with CKD. Previous studies 
from the Third National Health and Nutrition Examination Survey and Study to Evaluate Early Kidney Disease 
demonstrated that vitamin D deficiency was independently associated with anemia in patients with CKD9,28. 
Several studies using a burst-forming unit-erythroid assay have suggested a direct effect of vitamin D on prolifera-
tion of erythroid precursor cells obtained from patients with CKD, with a synergistic effect with EPO29–31. In addi-
tion, vitamin D deficiency is associated with secondary hyperparathyroidism, which can induce bone marrow 
fibrosis and suppress erythropoiesis in CKD32. Considering the fact that FGF23 decreases 1,25-dihydroxyvitamin 
D3 levels by inhibiting CYP27B1 (1-α-hydroxylase) and by stimulating CYP24A1 (24-hydroxylase)10,11, vitamin 
D deficiency may be a potential mechanistic link that can explain the relationship between FGF23 and anemia. 
In this study, however, the effect of FGF23 on the development of anemia was not altered after adjustment for 
1,25-dihydroxyvitamin D3 levels. Moreover, there was no significant interaction between FGF23-related anemia 
and 1,25-dihydroxyvitamin D3 levels in subgroup analysis. These findings indirectly support the result from 
the aforementioned experimental study, in which abolishing vitamin D signaling from FGF23 null mice did not 
resolve the erythropoietic abnormalities20.
It is well known that iron deficiency is an important factor that can promote anemia in CKD. Interestingly, 
animal and human studies demonstrated that absolute and functional iron deficiency stimulates FGF23 pro-
duction33–36. In line with these findings, our data showed that FGF23 was inversely correlated with iron pro-
files, including iron and TSAT, and positively correlated with hepcidin, which induces functional iron deficiency 
through iron sequestration and inhibition of iron absorption in the gastrointestinal tract37. Furthermore, sub-
group analyses showed that a significant association between high FGF23 levels and the development of anemia 
was evident in patients with iron deficiency and high inflammatory status. It can be presumed that iron deficiency 
induces anemia either directly or indirectly through a negative impact of FGF23 on erythropoiesis.
Model 1a Model 2b Model 3c Model 4d
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
FGF23 quartile
Quartile 1 Reference Reference Reference Reference
Quartile 2 1.65 (1.13–2.40) 0.009 1.48 (1.02–2.16) 0.04 1.23 (0.81–1.87) 0.34 1.22 (0.80–1.85) 0.36
Quartile 3 2.55 (1.80–3.62) <0.001 2.15 (1.51–3.07) <0.001 1.71 (1.15–2.54) 0.008 1.66 (1.11–2.47) 0.01
Quartile 4 2.94 (2.07–4.17) <0.001 2.42 (1.70–3.45) <0.001 1.95 (1.31–2.90) 0.001 1.84 (1.23–2.76) 0.003
FGF23 (per 1 log) 1.32 (1.22–1.43) <0.001 1.26 (1.16–1.36) <0.001 1.19 (1.08–1.31) <0.001 1.17 (1.07–1.29) 0.001
Table 5. Multivariable Cox regression model for the development of anemia. Note: FGF23 entered as a 
categorical and continuous form (log transformed). aUnadjusted model. bAdjusted for age, sex, DM, BMI, 
SBP, CCI, smoking status. cAdjusted for Model 2 + eGFR, albumin, phosphorus, 1,25(OH)2 vitamin D, iron 
deficiency, hepcidin*, CRP*, and proteinuria*. dAdjusted for Model 3 + iron replacement and ESA therapy. 
*Variables were log transformed. Abbreviations: FGF23, fibroblast growth factor 23; DM, diabetes mellitus; 
BMI, body mass index; SBP, systolic blood pressure; CCI, Charlson comorbidity index; eGFR, estimated 
glomerular filtration rate; CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent.
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Subgroup analyses showed that the use of RAS blockers can affect the relationship between FGF23 and the devel-
opment of anemia. This association was evident in patients treated with RAS blockers (HR, 1.18; 95% CI, 1.07–1.29; 
P = 0.001), but not in patients without RAS blockers (HR, 1.04; 95% CI, 0.75–1.45; P = 0.81). Several experimental 
and clinical studies have suggested possible association between renin-angiotensin-aldosterone system and eryth-
ropoiesis38–41. Angiotensin II were demonstrated to be a physiologically important regulator of erythropoiesis, both 
as a growth factor of erythroid progenitors, and as an erythropoietin secretagogue to maintain increased erythro-
poietin41. In addition, serum aldosterone levels were demonstrated to play a role in the relationship between FGF23 
and hemoglobin levels21. Moreover, RAS activation is reported to induce FGF23 resistance42. These findings together 
suggest that negative effect of FGF23 on erythropoiesis can be more evident in low renin-angiotensin-aldosterone 
status. Future studies are required to clarify the impact of RAS on FGF23-associated anemia.
Several shortcomings of this study should be discussed. First, because this is an observational study, it is pos-
sible that potential confounding factors were not entirely controlled. However, this study included a large number 
of patients and yielded consistent results in various multivariable Cox models after rigorous adjustment. Second, 
patients in our study had relatively higher eGFR than those in a previous study21; thus, the association between 
FGF23 and anemia needs to be verified in patients with advanced stages of CKD. Although there was no signifi-
cant interaction between FGF23-related anemia and kidney function, subgroup analyses showed that association 
between FGF23 levels and incident anemia was particularly evident in patients with eGFR >30 ml·min−1·1.73 m−2. 
Furthermore, high FGF23 levels were also significantly associated with the future development of anemia in patients 
with low disease severity (e.g., with well-controlled BP, no diabetes, no obesity, and low comorbid conditions). 
Presumably, there are many other factors that can affect erythropoiesis in uremic conditions. These unseen factors 
seem to have overwhelmed the effect of FGF23 on anemia in patients with a high disease burden. Third, although 
iron deficiency modulates FGF2333–36, our study did not show that ferritin levels were correlated with FGF23 levels. 
However, it should be noted that ferritin is an acute-phase reactant and can be elevated in response to uremic inflam-
matory condition despite the presence of functional iron deficiency. This can explain a poor correlation between fer-
ritin and FGF23 in CKD. Finally, we performed a single measurement of FGF23 concentrations at baseline and had 
no data for follow-up measurements. It would be interesting to see whether a change of FGF23 level is concordant to 
that of hemoglobin level. Further longitudinal studies are required to examine this relationship.
Figure 4. Subgroup analyses for association between FGF23 and anemia development. Abbreviations: DM, 
diabetes mellitus; SBP, systolic blood pressure; BMI, body mass index; CCI, Charlson comorbidity index; RAS, 
renin-angiotensin system; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein.
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In conclusion, this study showed that serum FGF23 levels were inversely correlated with hemoglobin levels 
in patients with CKD and that patients with high FGF23 levels were more likely to have anemia. Furthermore, in 
patients without anemia at baseline, elevated FGF23 levels were associated with an increased risk of new devel-
opment of anemia. Our findings suggest that FGF23 can be a useful predictor of anemia in patients with CKD. 
Further studies are required to clarify the mechanism for FGF23-associated anemia in these patients.
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